r i : v a l
Knowledge Base
Knowledge Base
ri:val Knowledge Base
Newsletters
- High Finance in Biotech?
- Phase 2a and 2b transition probabilities
- How to determine fair option agreement terms?
- Early-stage project valuation myths
- NPV vs. rNPV
- Deal Analysis: CellGenesys - Takeda
- Survey on discount rates in biotech
- Should we discount by project or by company? (continued)
- Should we discount by project or by company?
- Deal Analysis: Adnexus - BMS
- Black's risk-free discounting rule
- Deal Analysis: Ardea - Bayer
- How Biotech Stocks Behave
- Deal Analysis: Plexxikon - Roche
- Why drug prices must be high
- Deal Analysis: Celldex - Pfizer
- Staged Take-Overs: New Deal Structure on the Rise
- Risk Premium
- Deal Analysis: KyowaKirin - Amgen
- Biotech Success Rates: NCEs vs. Biologicals
- Real Options: Dos and Don'ts
- Optimal Portfolio Structure
- Employee Stock Option Plans
- Biotech Success Rates: Going the Wrong Way
- Early-Stage Licensing: How to Determine Sublicensing Terms
- Avance Survey on Financial Crisis and Impact on Pharma and Biotech Companies
- Funny Valuations
- Why are royalties up-tiered?
- Arbitrary Terminal Value
- P/E Ratio for Biotech Valuation.
- Multi-Indication Deals - How to Value Them.
- Co-Development Deals - How to determine a Fair Share?
- Biotech Taxes - Effects on Valuation?
- Reading Deals - How to Interpret Licensing Deals
- Non-Dilutive Financing Alternatives
- Forecasting Sales - Competition Scenarios
- Discount Rates in Pharma and Biotech
- Discovery & Preclinical Deals: What's realistic?
- The US$ 1 bio drug. A fairytale
What's Next
To take advantage of ri:val software or to learn how ri:val can benefit you, contact us by phone or email us at info@avance.ch
Find out about having a personal or online demo.
Get on the ri:val mailing list and sign up for our email newsletter to discover what's new about ri:val and topical industry information.
